SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

GMP challenges holding back Big Pharma's personalised vaccine uptake, says immatics

Biopharmas struggle to comply with GMP requirements for personalised meds and are reluctant to invest according to German firm immatics, which is leading a consortium to advance individual cancer vaccines.

GMP questions an anchor on biopharma investment
Dispatches from BioProcess International

Shift to single-use means end users ceding more control to suppliers, experts say

As single-use technology replaces traditional stainless steel technology in biomanufacturing, suppliers will own a larger portion of the supply chain, which is creating anxiety for end users such as Pfizer and Merck, experts say.

Amgen studying what impact switching to 'biosimilar' Aranesp has on patients

Amgen is recruiting chronic kidney disease (CKD) patients to assess what impact switching to a 'biosimilar' version of its blood cell booster Aranesp has had on their disease.

Biotherapeutics need general chapters not individual Ph. Eur. monographs says EGA

European generic drugmakers want biopharmaceuticals to have general chapters in the European Pharmacopoeia rather than individual monographs for ingredients to aid development of biosimilars.

editor's blog

Walk like an Egyptian? Not if you have ankylosing spondylitis says study

Ramesses II didn't need Enbrel, Remicade or Humira according to a study that rejects the idea the pharaoh was plagued, all puns intended, by ankylosing spondylitis.

Future trends: Rise of mAbs and fall of 20,000L bioreactors says consultant

Increased efficiency, local manufacturing and specialty products are driving demand for smaller more flexible facilities, according to bioprocessing consultant Howard Levine.

Spotlight

Greenpeace: Industry needs greener disposal for single-use systems

Greenpeace: Industry needs greener disposal methods for single-use systems

Common environmentally practices for single-use systems must be adapted before industry “becomes too set in its ways,”...

Seattle Genetics, Genmab enter ADC collaboration worth up to $211m

Seattle Genetics, Genmab enter ADC collaboration worth up to $211m

Seattle Genetics and Genmab have entered into another antibody-drug conjugate (ADC)partnership under which Genmab will pay $11m...

Purple not the new orange: US FDA biopharmaceuticals list lacks dates

Purple not yet the new orange: US FDA biopharmaceuticals list lacks dates

A new list of biopharmaceuticals published by the US FDA provides limited information with only the entries...

Better together? Biosimilars sector says aye
infographic feature

Better together? biosimilars sector says aye

Partnerships are a mixed bag.For every oppressed group yearning to throw off the yoke of their imperialist...

Shifting pipelines drive AMRI to expand protein expression services

Shifting pipelines drive AMRI to expand protein expression services

AMRI has added protein expression and purification services to its drug discovery services citing the shift in...

Asthma: It’s a mAb, mAb, mAb, mAb world says analyst

Asthma: It’s a mAb, mAb, mAb, mAb world says analyst

Sanofi and Regeneron may overtake Roche and Astrazeneca at the head of the increasingly monoclonal antibody (mAb)...

On demand Supplier Webinars

Biosimilars: developing, manufacturing and selling
William Reed Business Media
All supplier webinars